Not intended for UK-based media Long-term follow-up of the Phase III JAVELIN Bladder 100 study demonstrated median overall survival from start of chemotherapy of 29.7 months among patients receiving
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial.
Not intended for US-, Canada- and UK-based media First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative
New Phase II data show evobrutinib sustained low annualized relapse rates (ARRs) and had no new safety signals at 2.5 years the longest follow-up of any Bruton's tyrosine kinase inhibitor in multiple